GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Mereo BioPharma
Mereo BioPharma is a biotech company that acquires and develops promising drugs abandoned by major pharmaceutical companies. Its share price represents a portfolio bet on its team's ability to successfully bring these assets to approval or partnership.
Share prices of companies in the market segment - Specialized pharma
Mereo BioPharma (MREO) is a biopharmaceutical company that acquires and develops promising clinical programs for the treatment of rare diseases and oncology. We classify it as a "Specialty Pharmaceutical." The chart below shows general trends in the orphan drug biotechnology sector.
Broad Market Index - GURU.Markets
Mereo BioPharma is a biopharmaceutical company that acquires and develops drugs for the treatment of rare diseases and oncology. Its strategy makes it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how Mereo compares to the overall market dynamics.
Change in the price of a company, segment, and market as a whole per day
MREO - Daily change in the company's share price Mereo BioPharma
Shares of Mereo BioPharma, a biopharmaceutical company, are highly volatile. Change_co measures market reaction to clinical trial data in rare diseases. This metric is an important component of formulas on System.GURU.Markets that assess biotech risks.
Daily change in the price of a set of shares in a market segment - Specialized pharma
Mereo BioPharma Group plc is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with MREO's performance, which focuses on rare diseases, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Mereo is a biopharmaceutical company specializing in drugs for rare diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Mereo's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Mereo BioPharma
For Mereo BioPharma Group, year-on-year performance is a story of developing drugs for rare diseases. Its 12-month market capitalization depends on progress in clinical trials and its ability to partner with major pharmaceutical companies to further develop and commercialize its most promising candidates.
Annual dynamics of market capitalization of the market segment - Specialized pharma
Mereo BioPharma Group plc is a biotechnology company that acquires and develops drugs for the treatment of rare diseases. Its model is designed to diversify risks. The chart shows how the market evaluates its development pipeline and its ability to successfully commercialize drugs.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Mereo BioPharma is a clinical-stage biotech company whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Mereo BioPharma
Mereo, a biopharmaceutical company, has speculative price movements. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials of its drugs for rare diseases, as well as partnerships with major pharmaceutical companies.
Monthly dynamics of market capitalization of the market segment - Specialized pharma
Biotech companies specializing in rare diseases often build their businesses by acquiring and developing promising assets. The dynamics of this sector, shown in the chart, reflect the risks and potential of this strategy. Mereo BioPharma also operates under this model.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Mereo BioPharma is a biopharmaceutical company specializing in rare diseases. Its shares move in sync with news about clinical trials and partnerships. Their performance is completely disconnected from the broader market and is a bet on scientific success.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Mereo BioPharma
Mereo BioPharma acquires and develops drugs for rare diseases that have been shelved by major pharmaceutical companies. Its weekly share price performance reflects the clinical data on these "revived" assets and its ability to bring them to regulatory approval.
Weekly dynamics of market capitalization of the market segment - Specialized pharma
Biotech companies working with rare diseases, like Mereo BioPharma, are driven by news of clinical trials. The success or failure of one player often impacts the entire niche. The chart below shows this overall pulse, allowing one to assess how promising the market perceives Mereo's drug rescue strategy.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Mereo BioPharma is a biotech company that acquires and develops drugs to treat rare diseases. Its performance depends on the success of its portfolio strategy and trial news. The chart shows how uncorrelated its stock is with the broader market.
Market capitalization of the company, segment and market as a whole
MREO - Market capitalization of the company Mereo BioPharma
Mereo BioPharma's market capitalization reflects investors' assessment of its strategy for acquiring and developing drugs for rare diseases. The chart shows how the market values its pipeline of candidates acquired from major pharmaceutical companies. Its dynamics depend on the success of clinical trials and the ability to form profitable partnerships.
MREO - Share of the company's market capitalization Mereo BioPharma within the market segment - Specialized pharma
Mereo BioPharma is a biopharmaceutical company that acquires and develops promising drugs, often from large pharmaceutical companies that have decided to change their focus. In the specialty pharmaceuticals segment, its market capitalization reflects the value and potential of its portfolio. The company's market capitalization reflects its ability to bring these "rescued" assets to commercial success.
Market capitalization of the market segment - Specialized pharma
This graph shows the overall value of the entire pharmaceutical sector. For Mereo BioPharma, with its model of "rescuing" and developing promising drugs from other companies, this line represents a map of opportunities. A rising graph indicates that the industry is increasingly diversifying into attractive assets that the company can acquire and bring to market.
Market capitalization of all companies included in a broad market index - GURU.Markets
Mereo BioPharma acquires and develops drugs for the treatment of rare diseases. Its market capitalization is determined by its portfolio and its ability to bring promising molecules to market. This is the market share of the business that "rescues" promising drugs.
Book value capitalization of the company, segment and market as a whole
MREO - Book value capitalization of the company Mereo BioPharma
Mereo BioPharma is a biopharmaceutical company that acquires and develops drugs for the treatment of rare diseases. Its book value is its financial resources and development pipeline. This is its capital for advancing drugs through clinical trials. How has this value changed? The chart below shows.
MREO - Share of the company's book capitalization Mereo BioPharma within the market segment - Specialized pharma
Mereo BioPharma is a biopharmaceutical company that acquires and develops promising drugs. Although it outsources manufacturing, its balance sheet reflects the value of its R&D infrastructure and offices where clinical trials are managed. The chart shows its share of operating assets in this pharmaceutical segment.
Market segment balance sheet capitalization - Specialized pharma
Mereo BioPharma, a biopharmaceutical company, has a lightweight model. It acquires and develops drugs, often outsourcing R&D and manufacturing. The biotech sector's BCap_Seg chart serves as a backdrop to its strategy of being flexible and focused on portfolio management.
Book value of all companies included in the broad market index - GURU.Markets
Mereo BioPharma's balance sheet isn't made up of factories, but rather a portfolio of several clinical programs for the treatment of rare diseases acquired from major pharmaceutical companies. The company's assets are its intellectual property and research data. The chart below shows how this "portfolio" biotech stacks up against other companies.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Mereo BioPharma
Mereo's balance sheet represents its R&D portfolio. Its market value, which is below its book value, reflects investor uncertainty about the success of its clinical trials. The chart represents a discount for the high risk inherent in biotech development.
Market to book capitalization ratio in a market segment - Specialized pharma
Mereo BioPharma is a biotech company that acquires and develops drugs for rare diseases. Its valuation on this chart reflects its ability to identify promising candidates and successfully conduct clinical trials, which requires expertise.
Market to book capitalization ratio for the market as a whole
Mereo BioPharma is a biotech company that acquires and develops drugs for rare diseases. Its value is derived from the potential of its clinical pipeline. This chart helps assess the premium or discount investors are placing on its business model of identifying undervalued assets.
Debts of the company, segment and market as a whole
MREO - Company debts Mereo BioPharma
Mereo BioPharma, a company that acquires and develops promising drugs from other pharmaceutical companies, uses capital to fund clinical trials. This chart shows how the company manages its portfolio of multiple assets as it seeks to advance them to the partnership or sale stage, which requires flexible financial management.
Market segment debts - Specialized pharma
Mereo BioPharma is a biotech company that acquires and develops promising drugs from large pharmaceutical companies. Its financial strategy is focused on effectively managing its clinical pipeline. This chart shows how the company finances these developments, likely primarily through equity and partnerships.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Mereo BioPharma
Mereo BioPharma is a biopharmaceutical company that acquires and develops drugs for rare diseases abandoned by other companies. This chart shows how the company finances these projects. It reflects the financial risk associated with reviving and refining risky but potentially valuable medical assets.
Market segment debt to market segment book capitalization - Specialized pharma
Mereo BioPharma acquires and develops promising drugs for rare diseases that have been shelved by major pharmaceutical companies. This model mitigates early-stage R&D risks. The chart shows debt trends in the biotech sector, providing context for assessing how Mereo finances the development and testing of its assets.
Debt to book value of all companies in the market
Mereo BioPharma Group acquires and develops drugs for rare diseases, which requires both expertise in valuing research assets and raising capital. This chart, showing the overall market debt burden, provides context. It helps assess how the company finances its development pipeline and how its debt management strategy compares to the biotech sector.
P/E of the company, segment and market as a whole
P/E - Mereo BioPharma
Mereo BioPharma is a biopharmaceutical company that acquires and develops promising drugs for the treatment of rare diseases and oncology. This chart shows how the market evaluates its strategy. This evaluation depends on the success of its portfolio assets in clinical trials and its ability to form profitable partnerships.
P/E of the market segment - Specialized pharma
Mereo BioPharma is a biopharmaceutical company that acquires and develops promising drugs. This chart shows the average valuation for the biotech sector. It helps understand how investors view its business model and its ability to select successful projects for further development.
P/E of the market as a whole
Mereo BioPharma Group is a biopharmaceutical company focused on acquiring and developing innovative drugs for rare diseases. This chart reflects the overall risk appetite of investors in the biotech sector. It helps understand whether MREO's valuation is based on the potential of its drug portfolio or whether it moves in tandem with overall industry sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Mereo BioPharma
Mereo BioPharma is a biopharmaceutical company that acquires and develops drugs for the treatment of rare diseases and oncology. Future profits depend on the success of its portfolio. This chart shows how the market evaluates its ability to select promising assets and bring them to commercialization.
%20P%2FE%20Mereo%20BioPharma&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Mereo-BioPharma&v=1772591706757 "Chart of the company's future (projected) P/E Mereo BioPharma")
Future (projected) P/E of the market segment - Specialized pharma
Mereo BioPharma is a biotech company that acquires and develops promising drug candidates from other companies for the treatment of rare diseases and oncology. This chart reflects expectations for its future profitability, showing how the market evaluates its ability to select successful assets and bring them to the next stages of development.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Specialized-pharma&v=1772591706826 "Future (projected) P/E graph of the market segment - Specialized pharma")
Future (projected) P/E of the market as a whole
Mereo BioPharma acquires and develops promising drugs for rare diseases that have been shelved by major pharmaceutical companies. This sentiment chart shows investor appetite for risky but potentially undervalued biotech assets.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772591706891 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Mereo BioPharma
Mereo BioPharma is a biopharmaceutical company that acquires and develops promising clinical programs from other companies. This chart illustrates its portfolio strategy. Profitability depends on its ability to select successful drug candidates and bring them to partnership or sale.
Profit of companies in the market segment - Specialized pharma
Mereo BioPharma is a biopharmaceutical company that acquires and develops drugs for the treatment of rare diseases. Its business model is to bring promising but stalled projects from other companies to fruition. Its profitability depends on the successful selection of assets and their advancement through clinical trials.
Overall market profit
Mereo BioPharma is a biotech company that acquires and develops promising drugs for the treatment of rare diseases and cancer. Its success depends on the right asset selection and clinical success. This graph, reflecting market conditions, influences its ability to finance development and the valuation of assets it may acquire.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Mereo BioPharma
Mereo BioPharma is a biopharmaceutical company that acquires and develops promising clinical programs abandoned by major pharmaceutical companies. This chart represents speculative expectations. Future profits depend on the successful advancement of these candidates through clinical trials and their subsequent sale or licensing.
%20profit%20of%20the%20company%20Mereo%20BioPharma&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Mereo-BioPharma&v=1772591707058 "Graph of future (projected) profit of the company Mereo BioPharma")
Future (predicted) profit of companies in the market segment - Specialized pharma
Mereo BioPharma is a biotech company that acquires and develops promising drugs for the treatment of rare diseases and cancer. The profitability forecasts for the pharmaceutical industry, shown in this chart, provide a general overview. This chart helps assess the success of Mereo's strategy in identifying and developing undervalued clinical assets.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Specialized-pharma&v=1772591707108 "Graph of future (predicted) profits of companies in a market segment - Specialized pharma")
Future (predicted) profit of the market as a whole
Mereo BioPharma is a biopharmaceutical company that acquires and develops drugs for rare diseases. Its business model relies on successful clinical trials and the ability to enter into partnerships or divest assets. The positive market environment, reflected in this chart, is improving the conditions for biotech deals.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772591707144 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Mereo BioPharma
Mereo BioPharma is a biopharmaceutical company that acquires and develops promising drug candidates for the treatment of rare diseases and oncology. It may not have stable revenues. This chart shows how the market values its pipeline and its ability to bring drugs to late-stage clinical trials.
P/S market segment - Specialized pharma
Mereo BioPharma is a biopharmaceutical company that acquires and develops promising drugs for the treatment of rare diseases and oncology. This chart shows the average revenue estimate in the sector. It helps assess how investors perceive the company's business model, which is based on developing a portfolio of acquired assets.
P/S of the market as a whole
Mereo BioPharma is a biopharmaceutical company that acquires and develops promising drugs for the treatment of rare diseases and oncology. The company focuses on candidates that have already completed certain stages of clinical trials. This chart helps understand how the market values companies with established revenues, which provides a backdrop for biotech analysis.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Mereo BioPharma
Mereo BioPharma is a biopharmaceutical company that acquires and develops drug candidates for the treatment of rare diseases and oncology. This chart reflects investor estimates of its potential future revenue. This valuation is a bet on its ability to successfully conduct clinical trials and commercialize its assets.
%20P%2FS%20Mereo%20BioPharma&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Mereo-BioPharma&v=1772591707305 "The graph of the company's future (projected) P/S Mereo BioPharma")
Future (projected) P/S of the market segment - Specialized pharma
Mereo BioPharma is a biopharmaceutical company focused on acquiring and developing drugs for rare diseases. This chart compares market expectations for its future revenue with other specialty pharmaceutical companies. This valuation reflects investors' confidence in its ability to identify promising assets and bring them to market.
%20P%2FS%20market%20segment%20graph%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Specialized-pharma&v=1772591707336 "Future (projected) P/S market segment graph - Specialized pharma")
Future (projected) P/S of the market as a whole
Mereo BioPharma is a biotechnology company that acquires and develops promising drugs for the treatment of rare diseases and cancer. Its value depends on the clinical success of its portfolio assets. This chart of general market expectations for Mereo is merely a backdrop; its future is determined by the results of clinical trials.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772591707368 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Mereo BioPharma
This chart shows the revenue of Mereo BioPharma, a biopharmaceutical company that acquires and develops promising drug candidates from other companies. Being in the clinical stage, it does not have stable commercial revenue. Any revenue it generates is likely the result of licensing the rights to its drugs to larger partners.
Sales of companies in the market segment - Specialized pharma
Mereo BioPharma is a biopharmaceutical company that acquires and develops promising drugs for rare diseases and oncology that have been shelved by major pharmaceutical companies. This chart shows revenue in the specialty pharmaceuticals sector. It reflects the company's unique business model of discovering "hidden gems" and bringing them to market.
Overall market sales
Mereo BioPharma is a biotech company that acquires and develops promising drugs for the treatment of rare diseases. Its success depends on the results of clinical trials and strategic partnerships. The overall economic situation, reflected in this chart, influences M&A activity in the pharmaceutical industry and the availability of capital for the biotech sector.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Mereo BioPharma
Mereo BioPharma is a clinical-stage biopharmaceutical company that acquires and develops drugs for the treatment of rare diseases and oncology. This projected revenue graph reflects expectations for its business model. Its dynamics depend on analysts' confidence in the successful results of clinical trials and the company's ability to secure lucrative partnerships.
%20sales%20of%20the%20company%20Mereo%20BioPharma&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Mereo-BioPharma&v=1772591707510 "Schedule of future (projected) sales of the company Mereo BioPharma")
Future (projected) sales of companies in the market segment - Specialized pharma
Mereo BioPharma is a biopharmaceutical company that acquires and develops promising drugs for rare diseases and oncology, often from large pharmaceutical companies. This chart shows projected revenues for the entire specialty pharmaceutical sector, reflecting the potential for developing drugs for orphan diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Specialized-pharma&v=1772591707514 "Schedule of future (projected) sales of companies in the market segment - Specialized pharma")
Future (projected) sales of the market as a whole
Mereo BioPharma is a biotechnology company that acquires and develops drugs for the treatment of rare diseases. Its business model depends on its ability to identify promising assets and the overall health of the biotechnology market. A positive economic environment facilitates capital raising and partnerships.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772591707532 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Mereo BioPharma
Mereo BioPharma is a company that acquires and develops promising drugs developed by other pharmaceutical companies. Its model is "smart bets" in R&D. The chart shows operating losses, which are investments in clinical trials of selected assets, in the hopes of bringing them to market or selling them profitably.
Market segment marginality - Specialized pharma
Mereo BioPharma is a biopharmaceutical company specializing in the acquisition and development of drugs for rare diseases. This chart reflects its financial performance. For a company with this model, outperforming competitors in profitability can be attributed to lucrative licensing agreements for the drugs it develops.
Market marginality as a whole
Mereo BioPharma is a biotech company that acquires and develops drugs to treat rare diseases. Its success depends on its ability to select promising assets and successfully move them through clinical trials, rather than on the state of the economy, as reflected in this chart.
Employees in the company, segment and market as a whole
Number of employees in the company Mereo BioPharma
Mereo BioPharma is a biotech company that acquires and develops promising clinical-stage drugs. This graph shows a small team. Its small staff reflects its business model, which focuses on managing a portfolio of projects rather than conducting fundamental research from scratch.
Share of the company's employees Mereo BioPharma within the market segment - Specialized pharma
Mereo BioPharma is a biotech company specializing in the acquisition and development of drugs for rare diseases. Its model involves a small team managing clinical programs. This chart illustrates its focus: a minimal staff means focusing on portfolio management rather than on in-house research.
Number of employees in the market segment - Specialized pharma
Mereo BioPharma is a biotech company that acquires and develops promising clinical programs from large pharmaceutical companies. This chart illustrates the company's "discover and develop" model. A small but experienced team evaluates assets and manages their development. Success depends on the correct selection of candidates and the effective execution of clinical trials.
Number of employees in the market as a whole
Mereo BioPharma is a biopharmaceutical company that acquires and develops promising drugs for the treatment of rare diseases and oncology. Its business model requires a small but highly qualified team. This total employment chart shows that biotech companies have a variety of strategies, some of which are based not on in-house research but on portfolio management.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Mereo BioPharma (MREO)
Mereo BioPharma is a biopharmaceutical company that acquires and develops promising drugs for rare diseases that have been shelved by major pharmaceutical companies. This chart shows the company's enormous market value per employee. Market value reflects the potential of its pipeline, not its current operations.
%20of%20the%20company%20Mereo%20BioPharma%20(MREO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Mereo-BioPharma-MREO&v=1772591708091 "Chart of market capitalization per employee (in thousands of dollars) of the company Mereo BioPharma (MREO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Specialized pharma
Mereo BioPharma is a biopharmaceutical company that acquires and develops promising drugs for rare diseases. This metric reflects the effectiveness of their business model. Their high market capitalization per employee demonstrates that their small team of experts is capable of effectively selecting and advancing clinical programs, creating significant value.
%20by%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Specialized-pharma&v=1772591708097 "Market capitalization per employee (in thousands of dollars) by market segment - Specialized pharma")
Market capitalization per employee (in thousands of dollars) for the overall market
Mereo BioPharma is a biopharmaceutical company that acquires and develops promising drugs from other companies. This indicator reflects a model based on asset selection expertise. A small team of professionals evaluates and advances clinical programs, enabling value creation without the expense of early-stage research.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772591708119 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Mereo BioPharma (MREO)
Mereo BioPharma is a biotech company that acquires and develops clinical-stage drugs for rare diseases. They are not profitable. This chart shows their loss per employee. This is a standard indicator of the "burn rate" of capital spent on expensive clinical trials.
%20Chart%20Mereo%20BioPharma%20(MREO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Mereo-BioPharma-MREO&v=1772591708134 "Company Profit Per Employee (in thousands of dollars) Chart Mereo BioPharma (MREO)")
Profit per employee (in thousands of dollars) in the market segment - Specialized pharma
Mereo BioPharma is a biotech company specializing in rare diseases. The company has no profit, only R&D expenses. This metric reflects the R&D capital burn per employee, which compares to the high industry costs typical of orphan drug development.
%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Specialized-pharma&v=1772591708141 "Chart of profit per employee (in thousands of dollars) in the market segment - Specialized pharma")
Profit per employee (in thousands of dollars) for the market as a whole
Mereo BioPharma is a biotech company that acquires and develops (brings to clinical stages) drugs for rare diseases. Their business isn't about starting from scratch, but rather about effectively conducting R&D. This graph shows the negative value—the cost of the team managing the development pipeline and conducting clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772591708262 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Mereo BioPharma (MREO)
Mereo BioPharma is a biopharmaceutical company that acquires and develops promising drugs for the treatment of rare diseases and cancer. This graph is typical for a clinical-stage company. Low or no revenue per employee is normal, as the focus is on developing the asset portfolio.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Mereo-BioPharma-MREO&v=1772591708283 "Sales chart per company employee Mereo BioPharma (MREO)")
Sales per employee in the market segment - Specialized pharma
Mereo BioPharma (MREO) is a biotech company that acquires and develops (clinically advances) promising drugs for the treatment of rare diseases and oncology. This chart shows the revenue (from partnerships) generated by each employee (scientist). This is an indicator of the effectiveness of their "discover and develop" business model.
Sales per employee for the market as a whole
Mereo BioPharma (MREO) is a biopharmaceutical company that acquires and develops (advances through clinical stages) promising drugs for the treatment of rare diseases and oncology. This is an R&D business. The company has no commercial revenue, which does not yet reflect effectiveness.
Short shares by company, segment and market as a whole
Shares shorted by company Mereo BioPharma (MREO)
Mereo BioPharma is a biotech company that acquires and develops drugs shelved by major pharmaceutical companies. This chart measures bearish bets. Bears are betting that these drugs were shelved for a reason, and that Mereo will also fail in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Mereo-BioPharma-MREO&v=1772591708417 "Short Shares Chart for the Company Mereo BioPharma (MREO)")
Shares shorted by market segment - Specialized pharma
Mereo BioPharma is a biotech company that acquires and develops drug candidates for rare diseases. This chart shows bearish sentiment. "Shorts" here are bets that their business model (acquiring other companies' developments) is ineffective or that their drugs will fail in the clinic.
Shares shorted by the overall market
Mereo BioPharma specializes in rare diseases. It's a biotech whose value is based almost entirely on future clinical trial expectations. This overall pessimism chart is critical for MREO. When market fear is high, risk appetite plummets, which hurts all speculative biotech stocks.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Mereo BioPharma (MREO)
Mereo BioPharma is a biotech company specializing in rare diseases. This chart measures the extremes of speculative sentiment. It shows when the stock is "overheated" (overbought) on positive lab news or "oversold" (bottomed out) amid a general cooling in the biotech sector.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Mereo-BioPharma-MREO&v=1772591708708 "RSI 14 indicator chart for the company's stock Mereo BioPharma (MREO)")
RSI 14 Market Segment - Specialized pharma
Mereo BioPharma is a biotech company specializing in developing drugs to treat rare diseases, particularly osteogenesis imperfecta (osteogenesis imperfecta). This chart measures the overall momentum in the rare disease biotech sector. It helps assess whether the entire segment is overheated by expectations.
RSI 14 for the overall market
Mereo BioPharma, a biotech company whose fate depends on this schedule, requires a constant influx of capital to fund expensive clinical trials. During periods of market euphoria, investors generously fund risky developments. During periods of panic, the "cash spigot" is turned off, and companies like MREO are forced to struggle to survive.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MREO (Mereo BioPharma)
Mereo BioPharma is a biotech company that acquires and develops drugs for rare diseases and oncology. This chart shows the average 12-month forecast of analysts. This represents their collective speculative bet that their R&D pipeline, particularly their drug for osteogenesis imperfecta, will be successful.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MREO-Mereo-BioPharma&v=1772591708920 "A chart showing analyst consensus forecasts for the expected stock price. MREO (Mereo BioPharma)")
The difference between the consensus estimate and the actual stock price MREO (Mereo BioPharma)
Mereo BioPharma is a biotech company that acquires and develops drug candidates for rare diseases, particularly osteogenesis imperfecta (osteogenesis imperfecta). This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their confidence in this R&D pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MREO-Mereo-BioPharma&v=1772591709018 "A chart showing the difference between the consensus forecast and the actual stock price. MREO (Mereo BioPharma)")
Analyst consensus forecast for stock prices by market segment - Specialized pharma
Mereo BioPharma is a biotech company that "rescues" promising but "deferred" R&D projects from large pharmaceutical companies, bringing them to the clinic (focusing on rare diseases). This chart shows general expectations for the specialty pharmaceutical sector. It reflects whether experts believe in this "R&D arbitrage" business model.
Analysts' consensus forecast for the overall market share price
Mereo BioPharma is a biotech company that acquires (or licenses) promising drugs for rare diseases from other companies and brings them to market. This chart shows the overall risk appetite. For Mereo, whose business model is to make smart bets on biotech, overall market optimism is important for funding and supporting the valuation of its portfolio.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Mereo BioPharma
Mereo BioPharma is a biotech company specializing in rescuing and developing promising drugs (primarily for rare diseases and oncology) that have been shelved by large pharmaceutical companies. This chart evaluates their R&D strategy, reflecting their ability to select winners and successfully bring them to clinical success or partnerships.
AKIMA Market Segment Index - Specialized pharma
Mereo BioPharma (MREO) is a clinical-stage biotech company based in the UK developing a portfolio of drugs for rare diseases (including osteogenesis imperfecta, a condition characterized by fragile bones). This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this R&D platform (MREO) differentiate it from the average pharma company?
The AKIM Index for the overall market
Mereo BioPharma is a biotech company developing treatments for rare diseases and oncology (Setrusumab). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this clinical development with a partnership model compares to the overall economic trends affecting healthcare.
